6 November 2025
If you are covering AstraZeneca’s latest financial results, please find below a comment from Sheena Berry, healthcare analyst at Quilter Cheviot:
“AstraZeneca posted another strong quarter, with product revenue up 11% and oncology continuing to drive performance, growing 18% on the back of key medicines such as Imfinzi, Tagrisso and Enhertu.
“The company is investing heavily in future growth, with R&D spend up 14% as it accelerates clinical trial recruitment and advances its pipeline. In the US, where AstraZeneca generates over 40% of its sales, revenues rose 9%. AstraZeneca is one of two pharmaceutical companies to have established an agreement with the US Government to lower the cost of medicines for American patients and has made a $50bn investment commitment into US manufacturing and R&D.
“Full-year guidance remains unchanged, with sales expected to rise by high single digits and core earnings by low double digits. With multiple positive Phase III readouts and drug approvals this year, AstraZeneca is entering a catalyst-rich period and remains on track toward its ambitious $80bn revenue target by 2030.”
